Immunovant Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2018 | $380.4K | $405.0K | $325.0K |
| Mar 2019 | $6.5M | $13.8M | $7.0M |
| Jun 2019 | $4.1M | $117.4M | $1.9M |
| Sep 2019 | $4.4M | $117.8M | $1.6M |
| Dec 2019 | $14.8M | $126.6M | $123.5M |
| Mar 2020 | $15.3M | $109.4M | $100.6M |
| Jun 2020 | $22.5M | $290.3M | $280.3M |
| Sep 2020 | $15.5M | $453.9M | $444.4M |
| Dec 2020 | $18.9M | $433.0M | $422.0M |
| Mar 2021 | $21.0M | $412.5M | $400.1M |
| Jun 2021 | $22.5M | $388.0M | $379.0M |
| Sep 2021 | $30.3M | $566.7M | $559.0M |
| Dec 2021 | $38.0M | $543.2M | $527.0M |
| Mar 2022 | $45.7M | $515.6M | $493.8M |
| Jun 2022 | $22.2M | $458.7M | $427.2M |
| Sep 2022 | $32.4M | $428.1M | $405.8M |
| Dec 2022 | $41.6M | $456.2M | $432.6M |
| Mar 2023 | $43.3M | $405.8M | $376.5M |
| Jun 2023 | $51.4M | $351.2M | $330.0M |
| Sep 2023 | $40.3M | $292.1M | $269.9M |
| Dec 2023 | $32.1M | $711.4M | $690.9M |
| Mar 2024 | $48.6M | $666.4M | $635.4M |
| Jun 2024 | $45.0M | $589.7M | $560.0M |
| Sep 2024 | $66.7M | $515.7M | $472.9M |
| Dec 2024 | $68.3M | $420.9M | $374.7M |
| Mar 2025 | $68.8M | $776.2M | $714.0M |
| Jun 2025 | $52.9M | $661.4M | $598.9M |
| Sep 2025 | $63.3M | $583.0M | $521.9M |
| Dec 2025 | $66.3M | $1.05B | $994.5M |
| Mar 2026 | $104.4M | $957.0M | $902.1M |
| Jun 2026 | $117.1M | $852.5M | $797.8M |